Background-Preeclampsia is a prevalent life-threatening hypertensive disorder of pregnancy. The circulating antiangiogenic factor, soluble endoglin (sEng), is elevated in the blood circulation of women with preeclampsia and contributes to disease pathology; however, the underlying mechanisms responsible for its induction in preeclampsia are unknown. Methods and Results-Here, we discovered that a circulating autoantibody, the angiotensin receptor agonistic autoantibody (AT 1 -AA), stimulates sEng production via AT 1 angiotensin receptor activation in pregnant mice but not in nonpregnant mice. We subsequently demonstrated that the placenta is a major source contributing to sEng induction in vivo and that AT 1 -AA-injected pregnant mice display impaired placental angiogenesis. Using drug screening, we identified tumor necrosis factor-␣ as a circulating factor increased in the serum of autoantibody-injected pregnant mice contributing to AT 1 -AA-mediated sEng induction in human umbilical vascular endothelial cells. Subsequently, among all the drugs screened, we found that hemin, an inducer of heme oxygenase, functions as a break to control AT 1 -AA-mediated sEng induction by suppressing tumor necrosis factor-␣ signaling in human umbilical vascular endothelial cells. Finally, we demonstrated that the AT 1 -AA-mediated decreased angiogenesis seen in human placenta villous explants was attenuated by tumor necrosis factor-␣-neutralizing antibodies, soluble tumor necrosis factor-␣ receptors, and hemin by abolishing both sEng and soluble fms-like tyrosine kinase-1 induction. Conclusions-Our findings demonstrate that AT 1 -AA-mediated tumor necrosis factor-␣ induction, by overcoming its negative regulator, heme oxygenase-1, is a key underlying mechanism responsible for impaired placental angiogenesis by inducing both sEng and soluble fms-like tyrosine kinase-1 secretion from human villous explants. Our results provide important new targets for diagnosis and therapeutic intervention in the management of preeclampsia. (Circulation. 2010;121:436-444.)
P reeclampsia is a prevalent life-threatening hypertensive disorder of pregnancy with high maternal and fetal rates of morbidity and mortality. 1, 2 A growing body of evidence indicates that a circulating maternal autoantibody, the angiotensin II type I receptor agonistic autoantibody (AT 1 -AA), is a prominent component in the pathogenesis of preeclampsia. Numerous early studies demonstrated that AT 1 -AAs activate AT 1 receptors on a variety of cell types and provoke biological responses relevant to the pathophysiology of preeclampsia. [3] [4] [5] [6] [7] [8] Recently, we have extended these in vitro studies by showing that key features of preeclampsia are generated in pregnant mice injected with either total immunoglobulin G (IgG) or affinity-purified AT 1 -AAs from preeclamptic women. 9 These studies provided the first direct evidence for the pathogenic nature of AT 1 -AAs in preeclampsia.
Clinical Perspective on p 444
Recently, Levine et al 10 showed that a soluble form of endoglin (sEng) is present at significantly elevated levels in the circulation of women with preeclampsia compared with women with normotensive pregnancy and that the level of sEng correlated with disease severity. Endoglin is a cellsurface coreceptor for transforming growth factor-␤1 and -␤3 that is expressed mainly on endothelial cells and syncytiotrophoblasts. [11] [12] [13] The introduction of recombinant adenovirus vectors encoding sEng into pregnant rats resulted in mild hypertension and proteinuria. Notably, the introduction of viral vectors encoding sEng and soluble fms-like tyrosine kinase-1 (sFlt-1, a soluble form of vascular endothelial growth factor receptor-1) together into pregnant rats resulted in nephrotic-range proteinuria, severe hypertension, and the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets), a severe form of preeclampsia. These studies demonstrate that sEng contributes to preeclampsia. 14 However, factors and signaling pathways responsible for elevated sEng in women with preeclampsia were not determined.
Here, we show that AT 1 -AA induces the production of sEng in pregnant mice but not in nonpregnant mice by activation of AT 1 receptors and that the placenta is a major source of its induction in vivo. We further provide compelling mouse and human evidence that AT 1 -AA leads to impaired placental angiogenesis via AT 1 receptor activation. More important, we reveal that AT 1 -AA-mediated tumor necrosis factor-␣ (TNF-␣) induction, by overcoming its negative regulator, heme oxygenase-1 (HO-1), is a key underlying mechanism responsible for impaired placental angiogenesis by inducing both sEng and sFlt-1 secretion from human villous placental explants. Overall, our findings are the first to link maternal autoantibodies with increased TNF-␣, a prominent inflammatory cytokine, to contribute to impaired placental angiogenesis by inducing 2 key antiangiogenic factors, sFlt-1 and sEng. This study provides important new targets for diagnosis and therapeutic intervention in the management of preeclampsia.
Methods
For an expanded Methods sections, please refer to the online-only Data Supplement.
Introduction of Antibody Into Mice
All animal studies were reviewed and approved by the Animal Welfare Committee, University of Texas Houston Health Science Center. Forty-eight C57BL/6J pregnant and 32 nonpregnant mice (18 to 22 g; Harlan, Indianapolis, Ind) were used in our study. Experiments were performed in the following groups of mice: pregnant mice (nϭ32) or nonpregnant mice (nϭ32) with single (nϭ16) or double (nϭ16) injection of IgG purified from normotensive control subjects (nϭ8) or preeclamptic patients (nϭ8). In addition, some of the pregnant mice were coinjected with losartan (0.24 mg, a generous gift from Merck & Co, Inc, Rahway, NJ; nϭ8) or a 7-amino acid (7-aa) peptide (AFHYESQ; nϭ8) corresponding to an epitope on the second extracellular loop of the AT 1 receptor (1.5 mg). All of the mice were anesthetized with sodium pentobarbital (50 mg/kg IP), and concentrated IgG purified from 200 L normotensive control subjects (nϭ12) or patients' serum (nϭ14) (either combined or single individual) was introduced into pregnant mice (single injection on gestation day 13; for double injection, second injection on gestation day 14) or in nonpregnant mice (2 consecutive days by orbital sinus injection). IgG was prepared as previously described. [5] [6] [7] 9 We collected plasma and serum on multiple gestation days for determination of sEng and TNF-␣ concentration.
Results

IgG From Women With Preeclampsia Stimulates sEng Production in Pregnant Mice but Not Nonpregnant Mice via AT 1 Receptor Activation
To determine the potential role of pregnancy in the sEng induction by AT 1 -AA, we injected pregnant or nonpregnant mice with a single dose (gestation day 13) or a double dose (gestation days 13 and 14) of IgG from women with preeclampsia or women with a normotensive pregnancy. The single injection of IgG from women with preeclampsia did not induce a significant increase in sEng production by gestation day 18 in the pregnant mice compared with mice injected with IgG from women with a normotensive pregnancy ( Figure 1A ). However, a 4-fold increase in sEng was observed by gestation day 18 in pregnant mice that received a double injection of IgG from preeclamptic women compared with mice that received 2 injections of IgG from normotensive pregnant women ( Figure 1A) , which is similar to the increase seen in preeclamptic women. 10 Because 2 autoantibody injections were required to achieve a significant increase in sEng levels in pregnant mice, we chose the double-injection protocol for the remainder of the experiments presented here. Antibody-mediated induction of sEng production was blocked by coinjection with losartan, an AT 1 receptor antagonist, or with a 7-aa epitope peptide that blocks autoantibody-mediated AT 1 receptor activation ( Figure 1B) . These results indicate that IgG from preeclamptic women induced sEng production in pregnant mice via AT 1 receptor activation. In contrast to what we observed in pregnant mice, sEng in nonpregnant mice was not induced by IgG from women with preeclampsia or normotensive pregnant women after single or double injections ( Figure 1C ). Thus, these findings demonstrate that IgG from women with preeclampsia is capable of inducing sEng production via AT 1 receptor activation in pregnant mice but not in nonpregnant mice.
Placenta Is a Major Organ Contributing to sEng Production in Autoantibody-Injected Pregnant Mice
Next, to determine whether the placenta is a major source of sEng production and secretion, we measured Eng mRNA and protein levels in the mouse placenta and kidneys from pregnant mice injected with IgG as described above. We found that total Eng mRNA levels were increased in placenta tissue of mice injected with IgG from women with preeclampsia compared with placenta tissue of mice injected with IgG from women with normotensive pregnancies (Figure 2A and 2B), which suggests that AT 1 -AA-mediated sEng induction is at the mRNA level, a finding consistent with earlier human studies. 14 Similarly, we found that the abundance of intact Eng protein and the small amount of sEng remaining in the placentas were also induced in pregnant mice injected with IgG from preeclamptic women but not IgG from normotensive pregnant women ( Figure 2C through 2E). We consistently found that Eng protein levels were much lower in kidney samples and that there was no difference in mice injected with IgG from normotensive pregnant women or those with preeclampsia ( Figure 2C through 2E). Thus, these results provide direct evidence that placenta is a major organ contributing to sEng synthesis and secretion in autoantibody-injected pregnant mice.
Angiogenesis Is Impaired in Placentas of Autoantibody-Injected Pregnant Mice
To address whether AT 1 -AA-induced placenta-derived antiangiogenic factors led to impaired placental angiogenesis, we analyzed the vasculature of isolated mouse placentas by immunostaining using antibody recognizing CD31, an endothelial cell-specific marker. The results show that CD31 staining was less prominent in the labyrinth zone of the placentas of mice injected with IgG from women with preeclampsia than in those injected with IgG from normotensive pregnant women ( Figure  3A ). Coinjection of antibody with losartan or the 7-aa epitope peptide reduced this effect ( Figure 3A ). Quantitative image analysis of CD31 immunostaining demonstrated significantly less immunoreactivity in placenta sections from mice injected with IgG from preeclamptic women than in those from mice injected with IgG from normotensive pregnant women. Coinjection with losartan or the 7-aa epitope peptide significantly reduced the antiangiogenic effects of autoantibody injection ( Figure 3B ). Taken together, these results indicate that IgG from women with preeclampsia is capable of inducing placentaderived antiangiogenic factor production via AT 1 receptor activation and thereby contributes to decreased angiogenesis in the placenta of injected mice.
Serum From Mice Injected With IgG From Preeclamptic Women Stimulates sEng Secretion From Endothelial Cells
It is difficult to decipher the signaling pathways involved in AT 1 -AA-mediated sEng induction in intact animals; therefore, we chose endothelial cells, a recognized source of sEng production, as a cellular model system. Unexpectedly, we found that neither angiotensin II nor IgG from preeclamptic and normotensive pregnant women stimulated sEng production by the cultured endothelial cells ( Figure 4A ). These results suggest that increased sEng in autoantibody-injected pregnant mice did not result from direct AT 1 receptor activation. However, the production of sEng secretion was significantly increased by endothelial cells treated with serum of pregnant mice injected with IgG from preeclamptic women compared with that of cells cultured with serum of pregnant mice injected with normotensive IgG (Figure 4B ). The increase in sEng production did not occur when serum from mice that were coinjected with losartan or the 7-aa epitope peptide was used ( Figure 4B ). These results imply that serum from pregnant mice injected with IgG from preeclamptic women contains a factor that stimulates human sEng secretion from human endothelial cells. Furthermore, the causative factor present in the serum of antibody-injected mice is the result of AT 1 receptor activation.
TNF-␣ Is the Serum Factor in the Autoantibody-Injected Pregnant Mice Responsible for sEng Secretion From Endothelial Cells
To determine the circulating factors involved in AT 1 -AAmediated sEng induction in endothelial cells, we performed a drug screen to identify drugs that blocked the induction of sEng by serum from autoantibody-injected mice. Among all the drugs we have tested, we found that Enbrel, (Amgen, Thousand Oaks, CA 91320 and Wyeth Pharmaceuticals Inc., Collegeville, PA 19426) a soluble form of the TNF receptor, blocks serum-mediated sEng production by human endothelial cells (Figure 4B ), indicating that TNF-␣ is the serum factor responsible for inducing sEng production by endothelial cells. Next, we demonstrated that the ability of serum from autoantibody-injected mice to stimulate sEng production by cultured endothelial cells was also inhibited by anti-TNF-␣, a neutralizing antibody. Finally, we found that TNF-␣ directly stimulated sEng production by endothelial cells and that the induction was blocked by the presence of anti-TNF-␣ or Enbrel, a soluble form of the TNF receptor that also blocks TNF-␣ signaling. Taken together, these findings provide strong evidence that TNF-␣ was the serum factor in the autoantibody-injected pregnant mice responsible for AT 1 -AA-mediated sEng induction.
TNF-␣ Expression Is Increased in the Blood Circulation and Placentas of AutoantibodyInjected Pregnant Mice
The level of TNF-␣ is elevated in the blood circulation of women with preeclampsia, 15, 16 and it is possible that TNF-␣ may be induced by AT 1 -AA. To address this possibility, we measured TNF-␣ in autoantibody-injected pregnant mice. As shown in Figure 4D , the level of TNF-␣ was elevated in pregnant mice injected with IgG from preeclamptic women compared with that in mice injected with IgG from normotensive pregnant women. The autoantibody-mediated induction of TNF-␣ was prevented by coinjection with losartan or the 7-aa epitope peptide ( Figure 4D ), indicating that IgG from preeclamptic women induces TNF-␣ production in pregnant mice via AT 1 receptor activation. To determine whether TNF-␣ expression is upregulated in the placentas of antibody-injected mice, the placentas were collected on gestation day 18, 5 days after the initial IgG injection; then, total RNA was isolated, and real-time PCR was used to analyze the TNF-␣ transcript levels. The results ( Figure 4E) showed that the level of TNF-␣ transcripts increased nearly 5-fold in the placentas of mice injected with IgG from preeclamptic women compared with that in the placentas of mice injected with IgG from normotensive pregnant women. The autoantibody-mediated increase in the abundance of placental TNF-␣ RNA was attenuated by coinjection with losartan or the 7-aa epitope peptide. These data indicate that IgG from women with preeclampsia stimulates an increase in the abundance of TNF-␣ transcripts in the placentas via AT 1 receptor activation.
AT 1 -AA-Induced TNF-␣ Overcomes Its Downstream Negative Regulator, HO-1, to Induce sEng Secretion by Endothelial Cells
Among all the drugs we screened, we unexpectedly found that hemin, a well-known inducer of HO-1, blocked the ability of TNF-␣ to stimulate sEng production in human endothelial cells ( Figure 4C ). These results indicate that HO-1 functions as a break to control TNF-␣-induced sEng . TNF-␣ is the serum factor in autoantibody-injected pregnant mice that is responsible for induction of sEng production by endothelial cells. A, Human umbilical vascular endothelial cells were treated with angiotensin II or IgG from preeclamptic (PE) or normotensive (NT) pregnant women, and the concentration of sEng in cell culture supernatant was determined. Data are expressed as meanϮSEM of Ն3 experiments performed in duplicate (IgG from 12 to 14 patients was obtained for each group). B, Human umbilical vascular endothelial cells treated with serum from control pregnant mice and pregnant mice injected with IgG from normotensive pregnant or preeclamptic women or coinjected with preeclamptic IgG and losartan (PEϩlosartan) or 7-aa epitope peptide (PEϩ7-aa) on day 5 after the initial injections. Human umbilical vascular endothelial cells also treated with anti-TNF-␣, Enbrel, or hemin for 30 minutes before the addition of serum from pregnant mice injected with IgG from women with preeclampsia (mouse serum [PE]). After 24 hours, the sEng concentration in cell culture supernatants were measured. Data are expressed as meanϮSEM. Serum from 9 mice was obtained for each group. *PϽ0.05 vs cells treated with serum from mice injected with normotensive IgG; **PϽ0.05 vs cells treated with serum from mice injected with preeclamptic IgG. C, HUVECs were treated with TNF-␣ in the presence of TNF-␣-neutralizing antibody, Enbrel, or hemin for 24 hours. The concentration of sEng in cell culture media was determined by ELISA. Data are expressed as meanϮSEM of Ն3 experiments performed in duplicate (nϭ9 for each group). *PϽ0.01 vs control untreated cells; **PϽ0.05 vs cells treated with TNF-␣ alone. D, IgG from normotensive or preeclamptic pregnant women was introduced into pregnant mice at gestation days 13 and 14. Mouse serum was collected at gestation day 18, and levels of TNF-␣ were measured by ELISA. Data are expressed as meanϮSEM. nϭ5 to 8 for each group. *PϽ0.05 vs mice treated with normotensive IgG; **PϽ0.05 vs mice treated with preeclamptic IgG alone. E, Placentas were collected (nϭ8 to 10 for each group) at gestation day 18 (5 days after the initial IgG injection). Real-time polymerase chain reaction was performed to quantify the TNF-␣ mRNA abundance. Data are expressed as meanϮSEM. *PϽ0.001 vs normotensive IgG injection; **PϽ0.01 vs preeclamptic IgG injection.
secretion. More important, hemin also blocked the ability of serum obtained from pregnant mice injected with preeclamptic IgG to stimulate sEng production by human endothelial cells ( Figure 4B ). Thus, these findings provide the first evidence that HO-1 functions downstream of AT 1 -AAmediated TNF-␣ signaling to regulate sEng production.
AT 1 -AA-Induced TNF-␣ Production Contributes to sEng Induction From Human Placental Villous Explants
To extend mouse findings to humans and to assess the direct pathological role of autoantibody-mediated TNF-␣ signaling on sEng secretion in humans, we took advantage of human villous explants as an investigative tool. Immunohistostaining showed that Eng is evident in the syncytiotrophoblasts (fetus-derived cells) and endothelial cells (maternal origin) ( Figure 5A ), consistent with results published earlier. 14 Quantitative image analysis revealed that the intensity of immunostaining of Eng was higher in the samples treated with IgG from women with preeclampsia and that the increase in intensity was prevented by the presence of losartan or the 7-aa epitope peptide, indicating that the increase was mediated through AT 1 receptor activation ( Figure 5A and 5B). The increase in Eng immunostaining was also prevented by the presence of anti-TNF-␣, Enbrel, or hemin, indicating the requirement for TNF-␣ to overcome the negative regulation by HO-1 ( Figure  5A and 5B). Consistently, ELISA results demonstrated that AT 1 -AA significantly induced sEng secretion from human villous explants and that the induction was inhibited by compounds that block TNF-␣ signaling ( Figure 5D ). Overall, these findings not only reveal the localization of Eng in human placenta but also provide evidence that the induction of sEng by IgG from women with preeclampsia requires downstream TNF-␣ signaling through processes that are negatively regulated by HO-1.
AT 1 -AA-Induced TNF-␣ Signaling Plays an Important Role in Dysregulated Human Placental Angiogenesis
Consistent with our mouse findings, we found that treatment of explants with IgG from women with preeclampsia, in contrast to IgG from normotensive pregnant women, resulted in decreased CD31 immunostaining in human villous explants ( Figure 5A and 5C). The autoantibody-mediated decrease in CD31 immunostaining (ie, angiogenesis) was attenuated by the presence of losartan or the 7-aa peptide, as previously seen in pregnant mice. More important, we also found that anti-TNF-␣, Enbrel, or hemin prevented the reduced angiogenesis caused by AT 1 -AA in human villous explants ( Figure 5A and 5C), indicating that the reduced angiogenesis involved autoantibody-induced TNF-␣ signaling that was suppressed by HO-1. Overall, our studies suggest that autoantibody-induced TNF-␣ signaling plays an important role in decreased placental angiogenesis associated with preeclampsia.
TNF-␣ Signaling Contributes to AT 1 -AA-Mediated sFlt-1 Induction and Subsequent Impaired Placental Angiogenesis
In addition to sEng, sFlt-1 is a key antiangiogenic factor that is elevated in preeclampsia. We found that blocking AT 1 -AAmediated TNF-␣ signaling inhibited impaired placental angiogenesis ( Figure 5A and 5C), suggesting that TNF-␣ signaling contributes to abnormal placental angiogenesis by inducing not only sEng, as we have shown in Figure 5D , but also sFlt-1. To test this possibility, we measured sFlt-1 secretion in human placental villous explants after treatment with IgG from women with preeclampsia and normotensive pregnant women. The results ( Figure 5E ) showed that IgG from women with preeclampsia, in contrast to IgG from normotensive pregnant women, stimulated the production of sFlt-1. Similar to sEng, the induction was blocked by the presence of losartan or the 7-aa epitope peptide, indicating the requirement for AT 1 receptor activation. Autoantibody-induced sFlt-1 secretion was also prevented by the presence of human TNF-␣-neutralizing antibody, Enbrel, or hemin ( Figure 5E ), indicating the contributory role of TNF-␣ signaling in AT 1 -AA-mediated sFlt-1 induction in human villous explants. Together, these results significantly strengthen and broaden the pathophysiological role of AT 1 -AAmediated TNF-␣ induction in preeclampsia by linking both sFlt-1 and sEng with impaired angiogenesis in the human placenta.
Discussion
In this study, we have provided both in vivo mouse and in vitro human evidence that AT 1 -AA contributes to impaired placental angiogenesis via AT 1 receptor activation. Mechanistically, we have identified for the first time that the induction of sEng and sFlt-1 by AT 1 -AA is mediated through TNF-␣ signaling, which is negatively regulated by HO-1. Overall, both the mouse and human studies reported here provide strong evidence that AT 1 -AA-mediated TNF-␣ induction is an underlying mechanism for increased secretion of antiangiogenic factors and suggest that these signaling pathways contribute to impaired placental angiogenesis in preeclampsia and provide novel therapeutic targets for the disease (Figure 6 ).
Although the molecular basis for sEng induction in preeclampsia is poorly understood, hypoxia-inducible factor-1, transforming growth factor-␤, and TNF-␣ are reportedly involved in regulating the endoglin gene expression and the release of sEng from the placenta. 17, 18 We have shown here that IgG harbored by women with preeclampsia induces TNF-␣ production via AT 1 receptor activation, which in turn stimulates sEng production and its release into the maternal circulation from placenta but not kidney. These results indicate that AT 1 -AA is the causative factor responsible for sEng induction via TNF-␣ signaling and that the placenta is a major organ contributing to increased sEng secretion. Moreover, we provide compelling evidence that hemin, a well-known inducer of HO-1, attenuated AT 1 -AA-induced impaired human placental angiogenesis by blocking increased secretion of both sFlt-1 and sEng from human placenta villous explants. Thus, our studies provide the first evidence that HO-1 is a key intracellular molecule to control AT 1 -AA-induced dysregulated placental angiogenesis by inhibiting TNF-␣-mediated sFlt-1 and sEng induction.
HO-1 is an inducible, endoplasmic reticulum-bound enzyme that catalyzes the nicotinamide adenine dinucleotide phosphate-cytochrome P450 reductase-dependent oxidation of heme to biliverdin in a 3-step process that liberates CO and Fe 2ϩ . Thus, our present findings are strongly supported by earlier studies showing that HO-1 activity is protective against oxidant injury and inflammatory responses. 19 More important, it is known that women with preeclampsia have significantly decreased CO concentrations in their exhaled breath associated with a decreased expression of HO activity in their placentas. 20 Overall, we have provided both mouse and human evidence that AT 1 -AA-mediated TNF-␣ induction contributes to sEng and sFlt-1 induction and subsequent impaired placental angiogenesis by overcoming HO-1 signaling. TNF-␣ is a potent proinflammatory cytokine found at increased levels in the plasma of preeclamptic women. [21] [22] [23] Notably, recent studies demonstrate that there are significant increases in soluble TNF-␣ receptors in the plasma of preeclamptic patients. 24, 25 Although soluble TNF-␣ receptor is likely to bind with circulating TNF-␣ and decreases its availability as a ligand, we have provided both human and mouse evidence that AT 1 -AA-mediated TNF-␣ induction is responsible for both sEng and sFlt-1 induction and contributes to decreased placental angiogenesis, suggesting that increased TNF-␣ may contribute to the pathogenesis of preeclampsia. This implication is strongly supported by recent studies demonstrating that TNF-␣ is an important factor contributing to pathology in an experimental model of preeclampsia in rats based on reduced uterine perfusion pressure. 26, 27 More important, longterm perfusion of TNF-␣ at a level similar to that seen in the plasma of the preeclamptic women injected into pregnant rats leads to hypertension and proteinuria. 26 Although our studies presented here and others 21, 22, 26 provide strong evidence of a pathological role of TNF-␣ in preeclampsia, the relative importance of increased soluble TNF-␣ receptors in preeclampsia remains to be determined.
Although there is general agreement that plasma levels of TNF-␣ are higher in women with preeclampsia, 28 -30 conflicting reports have appeared about the placental contribution to increased levels of TNF-␣ in women with preeclampsia. 16, 31 Two early reports 28, 30 provided evidence for increased TNF-␣ in placentas from women with preeclampsia. Two subsequent reports 16, 31 did not find any significant difference in TNF-␣ levels between placentas from women with preeclampsia and placentas from normotensive pregnant women. Because TNF-␣ is synthesized and released from the placenta, the amount of TNF-␣ remaining in placental tissue may not accurately reflect the amount of TNF-␣ produced and released by the placenta. The abundance of TNF-␣ mRNA will more likely reflect the potential for TNF-␣ protein production. Data presented here show that autoantibody-mediated induction of sEng occurs only in pregnant animals and that TNF-␣ is a critical signaling intermediate. We saw a significant increase in TNF-␣ mRNA in the placentas of pregnant mice injected with IgG from women with preeclampsia. The increase was prevented by coinjection with losartan or the 7-aa epitope peptide, indicating that the increase was due to AT 1 -AAmediated AT 1 receptor activation. Thus, our AT 1 -AA-induced model of preeclampsia in mice and the data from human placenta villous explants suggest that the placenta is a major contributor to the resulting increase in circulating TNF-␣.
Conclusions
The work reported here is the first to link AT 1 -AA with the inflammatory system to regulate placenta-derived factors in both human and murine pregnancy and suggests that TNF-␣ is likely an important mediator of autoantibody-induced pathophysiology associated with preeclampsia resulting from increased production of sEng and sFlt-1. Therefore, the use of TNF-␣-neutralizing antibodies, soluble forms of TNF-␣ receptors, or inducers of HO-1 to blunt the effects of elevated TNF-␣ may be useful in the treatment of preeclampsia.
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This work was supported by National Institute of Health grants HL076558 and HD34130, a grant from the March of Dimes Foundation, and a grant from the Texas Higher Education Coordinating Board. Figure 6 . Working model of AT 1 -AA-mediated TNF-␣ induction in impaired placental angiogenesis in preeclampsia. This diagram represents a possible signaling cascade by which the autoantibody-mediated TNF-␣ induction overcomes HO-1, its negative regulator, and contributes to increased sEng and sFlt-1 secretion and subsequent impaired placental angiogenesis, a major feature in preeclampsia. This implies that blockade of TNF-␣ and AT 1 receptor or increasing HO-1 signaling may be a potential therapeutic strategy in the management of this serious disorder of pregnancy for both mothers and babies.
